Polynucleotides
4 min readPolynucleotides vs Exosomes: Legality and Evidence
Educational reading for licensed practitioners — not clinical or injection guidance.
Exosomes are among the most hyped words in aesthetics, promising cell-to-cell "messaging" and dramatic regeneration. Polynucleotides are quieter but increasingly relied upon. Patients and practitioners often ask which is better — but the more useful question, in 2026, is which one you can actually use with confidence. On both legality and the weight of evidence, the two are not on equal footing.
What Each One Is
Polynucleotides (PN/PDRN) are purified fragments of DNA, derived from cold-water fish, injected to support the skin's own repair processes — stimulating fibroblasts, improving hydration and calming inflammation. They are a defined, characterised medical product.
Exosomes are tiny extracellular vesicles that cells use to shuttle signalling molecules — proteins, lipids and genetic material — between one another. In aesthetics they are typically derived from cultured cells (often stem-cell sources) and marketed as concentrated regenerative "signals," usually applied topically after microneedling or laser. The concept is genuinely interesting; the products, and the claims made for them, are where the difficulty lies.
The Legality Gap
This is the decisive difference. No exosome product holds FDA approval for any aesthetic indication. Regulators have gone further than mere silence: the FDA has issued warnings about unapproved exosome products, and their use in skin has drawn scrutiny over sourcing, sterility and unverified claims. An exosome product presented to a patient as an approved, established treatment is being misrepresented.
Polynucleotides are not FDA-approved either — a caveat worth stating plainly, and one that also applies to Rejuran — but they occupy a clearer position: they are CE-marked and used routinely across the UK, Europe and Asia as regulated medical devices or products. "CE-marked and internationally used" is an accurate, defensible description. "FDA-approved" is not accurate for either category, and "approved" is simply wrong for exosomes.
The Evidence Gap
Beyond regulation, the published evidence base differs in maturity. Polynucleotides have a longer track record in regenerative medicine and a body of clinical use behind their aesthetic application, even if — as with much of the field — larger, high-quality trials are still accumulating. Exosome aesthetics is newer, more heterogeneous (products vary enormously by source and processing) and harder to evaluate, precisely because there is no standardisation. When two options make similar promises, the one with a more consistent product definition and a longer clinical history is the more rational default.
Why We Steer Toward Polynucleotides
For a clinic that wants a regenerative injectable it can stand behind, polynucleotides are the practical answer. Ranges such as Plinest, Newest, Rejuran and PolyPhil offer face-, eye- and scalp-specific presentations, all within a coherent regulatory framework. They pair naturally with microneedling and other skin-quality tools, and they let you have an honest conversation with a patient about what is known and what is not.
Exosomes are worth understanding as context — patients will ask about them — but they are not a product we stock or recommend for aesthetic use, and no responsible menu should present them as an approved alternative.
What About Topical Exosome Skincare?
A fair question is whether topical exosome-branded serums and masks are the same debate. They are not quite. Applying an exosome-labelled cosmetic to intact skin is a different proposition from injecting exosomes or driving them into needled skin, and it carries a different risk profile. But the same evidence caveat holds: cosmetic exosome claims are largely unstandardised and unverified, and the presence of "exosome" on a label tells you little about what is actually delivered or achieved. The regulatory point stands regardless of format — no exosome product is FDA-approved for an aesthetic indication, and none should be presented to patients as an approved regenerative treatment.
The Takeaway
On the two questions that matter most — can you use it lawfully and with confidence, and is it well enough characterised to trust — polynucleotides come out ahead of exosomes for aesthetic use in 2026. Neither is FDA-approved, but polynucleotides are CE-marked, defined and clinically established, while exosomes remain unapproved and unstandardised. When the goal is regeneration you can defend, PN is the sensible choice.
Explore the evidence-led options in the polynucleotide injections range.